Scientists Identify Mechanism Behind Ovarian Cancer Chemotherapy Resistance, Potential Reversal Strategy

Researchers have identified a key mechanism by which ovarian cancer cells develop resistance to chemotherapy, according to a study published in Nature Communications in August 2023. The findings, led by a team at the University of California, San Francisco (UCSF), could pave the way for new treatments to overcome this critical challenge in cancer care.

How Ovarian Cancer Cells Evade Chemotherapy

The study reveals that ovarian cancer cells exploit a protein called ALDH1A1 to neutralize the effects of platinum-based chemotherapy, the standard first-line treatment for the disease. ALDH1A1, which is overexpressed in certain cancer cells, detoxifies chemotherapeutic agents by breaking them down before they can damage DNA. This process allows cancer cells to survive and proliferate despite treatment.

“This protein acts like a shield, protecting cancer cells from the drugs meant to kill them,” said Dr. Sarah Lin, a cancer biologist at UCSF and co-author of the study. “By understanding this defense mechanism, we can target it to restore the effectiveness of chemotherapy.”

Blocking ALDH1A1 Restores Chemotherapy Sensitivity

In laboratory experiments, the research team used a compound called disulfiram, a drug traditionally used to treat alcohol dependence, to inhibit ALDH1A1. When combined with platinum-based chemotherapy, disulfiram significantly reduced tumor growth in mouse models of ovarian cancer. The results suggest that targeting ALDH1A1 could reverse resistance and improve treatment outcomes.

The findings align with earlier research from 2021, which linked ALDH1A1 overexpression to poorer survival rates in ovarian cancer patients. However, the new study is the first to demonstrate a viable strategy to counteract this resistance in preclinical models.

Implications for Future Treatments

The potential to repurpose disulfiram—a low-cost, well-tolerated drug—offers a promising avenue for clinical translation. Researchers are now exploring the development of more specific ALDH1A1 inhibitors to minimize side effects and enhance efficacy. A phase I clinical trial is expected to begin in 2024, according to UCSF’s press release.

“If these results hold in human trials, this could change the standard of care for ovarian cancer,” said Dr. Michael Chen, an oncologist at Memorial Sloan Kettering Cancer Center, who was not involved in the study. “Resistance remains a major obstacle, and this approach addresses a fundamental biological pathway.”

Why This Matters for Ovarian Cancer Patients

Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the U.S., with approximately 22,000 new cases diagnosed annually. While initial chemotherapy responses are often effective, resistance develops in over 70% of patients, leading to disease progression. The new research provides a targeted strategy to extend the benefits of existing treatments.

Comparisons with earlier studies highlight the significance of this work. A 2022 study in Journal of Clinical Oncology found that patients with ALDH1A1-high tumors had a 40% higher risk of recurrence. The UCSF team’s findings offer a direct intervention to mitigate this risk.

Next Steps and Challenges

While the preclinical results are encouraging, translating them into clinical practice requires further validation. Key questions remain about the optimal dosing of ALDH1A1 inhibitors, potential side effects, and whether the approach works across different ovarian cancer subtypes. Additionally, researchers must determine how to identify patients most likely to benefit from this strategy.

“This is a critical step, but we need to be cautious,” said Dr. Linda Nguyen, a gynecologic oncologist at the University of Michigan. “Repurposing drugs is faster than developing new ones, but we must ensure safety and effectiveness in diverse patient populations.”

The study underscores the importance of precision medicine in oncology, where treatments are tailored to the molecular characteristics of individual tumors. As research progresses, the hope is that targeting ALDH1A1 will become a standard component of ovarian cancer care, improving survival rates and quality of life for patients.